Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAA06 in Advanced Solid Tumors
NCT05190185Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAA06 in Malignant Melanoma (MM), lung cancer and colorectal cancer (CRC), sponsored by PersonGen BioTherapeutics. Primary endpoint: Assessment of the safety after B7-H3 chimeric antigen receptor T cells infusion at 3 months. Status: unknown.
02
Drugs
TAA06
03
Conditions
Malignant Melanoma (MM)lung cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05190185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190185.